Numinus MDMA Therapy Study Approved by Health Canada

Vancouver-based Numinus has received federal approval for a study on MDMA. The therapy study is sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and involves twenty people with post-traumatic stress disorder. The aim is to learn more about MDMA-assisted therapy, particularly for the treatment of PTSD and eating disorders. In addition, the researchers hope to gain a better understanding of how MDMA therapy could fit into society. Here are the details of this new development.

MDMA therapy

Under the Controlled Drugs and Substances Act, MDMA is currently classified as illegal unless it is approved for medical or scientific use. However, there is a growing movement to reform drug laws, especially when a drug has potential therapeutic value.

Studies by the Multidisciplinary Association for Psychedelic Studies (MAPS) show that MDMA can be an effective treatment for PTSD; “At the primary study endpoint (18 weeks after the start of the study), 28 of 42 (67%) participants in the MDMA group no longer met the diagnostic criteria for PTSD, compared with 12 of 37 (32%) participants in the placebo group after three sessions. ”

MDMA power study

On Monday, July 12, 2021, Health Canada confirmed approval for the Numinum study. Trials with 20 recruited participants will take place in Vancouver, BC this summer. The volunteers will go through a prep and medication study, both of which will take full days, before taking any medication. Rather than being housed in a traditional clinical setting, the meeting rooms are designed to create tranquility. Surrounded by plants and greenery, the MDMA therapy sessions are supervised by two therapists.

For more information on the therapeutic use of psychedelics, see the Multidisciplinary Association for Psychedelic Studies.

MAPS is seeking volunteers for this research study

You must be of legal age and have an up-to-date diagnosis of PTSD to participate. If you are interested, click here to apply.

Footnote (s)

https://www.nature.com/articles/s41591-021-01336-3
https://maps.org/research/mdma/ptsd/phase3